| Literature DB >> 16879738 |
Eiva Bernotiene1, Gaby Palmer, Cem Gabay.
Abstract
Leptin is produced primarily by adipocytes and functions in a feedback loop regulating body weight. Leptin deficiency results in severe obesity and a variety of endocrine abnormalities in animals and humans. Several studies indicated that leptin plays an important role in immune responses. It exerts protective anti-inflammatory effects in models of acute inflammation and during activation of innate immune responses. In contrast, leptin stimulates T lymphocyte responses, thus having rather a proinflammatory role in experimental models of autoimmune diseases. Clinical studies have so far yielded inconsistent results, suggesting a rather complex role for leptin in immune-mediated inflammatory conditions in humans.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16879738 PMCID: PMC1779438 DOI: 10.1186/ar2004
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Figure 1Structure and isoforms of mouse leptin receptor. Ob-Rb contains the longest intracellular domain, which is crucial for leptin signaling. Ob-Ra, Ob-Rc and Ob-Rd contain only short cytoplasmic domains. Ob-Re is a secreted isoform of the leptin receptor, lacking transmembrane and cytoplasmic parts. Cytokine receptor homology module (CRH)2 is the main binding site for leptin on the Ob-R. The Ig-like and the FN-III domains are critically involved in Ob-R activation. The role of CRH1 remains to be determined [111, 112]. FNIII, fibronectin type III domain; Ig-like, immunoglobulin-like fold.
Figure 2Mechanisms of leptin signaling. Upon leptin binding to Ob-Rb, the Janus kinase/signal transducer and activator of transcription (JAK/STAT), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K) pathways are activated. Akt, protein kinase B; Grb-2, growth receptor-bound-2; IRS, insulin receptor substrate; MEK, mitogen-activated protein kinase kinase; PIAS 3, protein inhibitor of activated STAT3; Raf, MEK-kinase; Ras, G-protein; SHP-2, SH2-domain containing protein tyrosine phosphatase; SOCS3, suppressor of cytokine signalling-3.
Effects of leptin or leptin receptor deficiency and leptin administration in experimental models of innate immune response in rodents
| Model | WT mice/rats | Ob-R-deficient mice/rats | Leptin administration | References | |
| LPS-induced lethality | Fasted mice: | ↑ Susceptibility | Fasted WT mice: effect reversed | [57] | |
| ↑ Susceptibility | ↓ IL-10 | ||||
| ↑ TNF-α | ↓ IL-1Ra | ||||
| ↓ Interferon-γ | |||||
| LPS ip | ↓ TNF-α | [64] | |||
| ↓ IL-6 | ↓ TNF-α | ||||
| ↓ IL-6 | |||||
| LPS-induced hepatotoxicity | ↑ Sensitivity | [60] | |||
| ↓ Hepatic CD4+NK | ↑ Sensitivity | ||||
| T cells | ↑ IFN-γ mRNA | ||||
| ↑ Serum IL-18 | ↓ IL-12 mRNA | ||||
| ↑ Hepatic IL-18 and IL-12 | |||||
| ↓ Hepatic IL-10 | |||||
| ↑ IFN-γ | |||||
| TNF-α-induced lethality | Fasted mice: | ↑ Susceptibility | ↑ Susceptibility | Fasted WT mice: effect not reversed | [58] |
| ↑ Susceptibility | |||||
| Leptin antagonist: | Leptin antagonist: effect partly reversed | ||||
| ↑ Susceptibility | |||||
| Pancreatitis | WT rats: protective effects | [62] | |||
| ↑ IL-4 | |||||
| ↓ TNF-α and IL-1β | |||||
| ↓ Clearance | [64] | ||||
| Smaller fraction of | |||||
| ↑ Leptin after infection | ↑ Mortality | [65] | |||
| ↑ Bacterial counts in lungs and blood | |||||
| [66] | |||||
| ↑ Yeast/g organ | |||||
| ↓ Leptin production | WT mice: | [55] | |||
| ↓ Severity | |||||
| ↓ IL-6 | |||||
| Zymosan-induced arthritis | ↑ Joint inflammation | ↑ Joint inflammation | [90] | ||
| ↑ SAA and IL-6 | ↑ SAA and IL-6 |
Up and down arrows indicate increase and decrease, respectively. ip, intraperitoneal; iv, intravenous; LPS, lipopolysaccharide; ob/ob, leptin deficient mice; Ob-R, leptin receptor; SAA, serum amyloid A; TNF, tumor necrosis factor; WT, wild-type.
Effects of leptin or leptin receptor deficiency and leptin administration in disease models mediated by adaptive immune responses in mice
| Models | WT mice | Leptin injection | References | ||
| Non-obese diabetic mice | ↑ Serum leptin before onset of diabetes | ↑ Destruction of insulin-producing β-cells | [75] | ||
| ↑ IFN-γ production by T lymphocytes | |||||
| AIA | ↓ Arthritis severity | ↓ Arthritis severity | [35] | ||
| ↓ Anti-mBSA Abs | ↓ Anti-mBSA Abs | ||||
| ↓ | ↓ | ||||
| ↓ IFN-γ and | ↓ IFN-γ and | ||||
| ↑ IL-10 production | ↑ IL-10 production | ||||
| EAE | ↑ Serum leptin before onset of EAE Serum leptin correlated with EAE susceptibility | ↓ Susceptibility | ↑ Severity in SJL females SJL males: become susceptible Restored susceptibility in | [42] | |
| Administration of anti-leptin Abs or soluble leptin receptors: | |||||
| ↓ Disease severity | |||||
| T-cell mediated hepatitis | Protected from liver damage | [70, 110] | |||
| ↓ TNF-α and IL-18 | |||||
| Colitis | ↓ Severity | [71] | |||
| ↓ Local release of proinflammatory cytokines | |||||
| Immune-mediated glomerulonephritis | Protected | [74] |
Up and down arrows indicate increase and decrease, respectively. Abs, antibodies; AIA, antigen-induced arthritis; db/db, leptin receptor deficient mice; EAE, autoimmune encephalomyelitis; ob/ob, leptin deficient mice; Th, T helper; TNF, tumor necrosis factor; WT, wild-type.
Circulating leptin levels in patients with immune-mediated inflammatory diseases
| Diseases | Leptin levels: patients versus healthy controls | Correlation of leptin levels with disease activity | Comments | References |
| RA | Elevated | No correlation with CRP | No data on BMI | [91] |
| RA | Elevated | Correlation with CRP | Different gender distribution in the groups | [92] |
| RA | Similar | No correlation | Correlated with BMI and percentage of body fat | [94] |
| RA | Similar | No correlation | Correlated with BMI | [95] |
| RA | Similar | Negative correlation with CRP | No effect of short course anti-TNF-α therapy | [97] |
| and IL-6 | on leptin levels | |||
| RA | Reduced | No correlation | No correlation with BMI, CRP or total fat mass | [96] |
| SLE | Elevated | No correlation | Correlated with BMI | [102] |
| Systemic sclerosis | Reduced | No correlation | Correlated with BMI | [103] |
| Behçet's disease | Elevated | Positive correlation | Gender ratio, age and BMI similar in patient and control groups | [104] |
| Multiple sclerosis | Similar | Positive correlation | Leptin levels increased before exacerbation and decreased after treatment with IFN-β | [100] |
| Multiple sclerosis | Similar | No correlation | Leptin levels increased in IFN-β treated patients during active disease and remission | [101] |
BMI, body mass index; CRP, C-reactive protein; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNF, tumor necrosis factor.